<DOC>
	<DOCNO>NCT02973594</DOCNO>
	<brief_summary>Heart failure reduce leave ventricular ejection fraction ( HFrEF ) common form chronic heart failure subject ≤ 75 year age . Beta-blocker therapy greatly reduce mortality improve ventricular function HFrEF patient , 30-40 % patient show improvement ventricular function beta blockade . An extensive gene signal network downstream beta1-adrenergic receptor , primary target beta-blocker therapy likely important development progression HFrEF . Pathologic change gene signal network reverse towards normal level ventricular function improve . One potential mechanism failure improve ventricular function HFrEF patient unresponsive beta blocker therapy lack heart rate reduction . Ivabradine FDA-approved medication believe therapeutic benefit HFrEF patient reduction heart rate independent beta-blockade . Ivabradine show reduce risk hospitalization worsen HF patient stable , symptomatic chronic heart failure reduce EF ( ≤ 35 % ) sinus rhythm rest heart rate ≥ 70 bpm maximally tolerated dos beta blocker contraindication beta blocker . Given high rate mortality hospitalization HFrEF patient even current therapy , large unmet need improve HFrEF therapy . The goal study test hypothesis heart rate reduction important antecedent improvement ventricular function , identify component beta1-adrenergic receptor gene signal network responsible improvement ventricular function cause heart rate reduction .</brief_summary>
	<brief_title>Pulse Reduction On Beta-blocker Ivabradine Therapy</brief_title>
	<detailed_description>The Pulse Reduction Beta-blocker Ivabradine Therapy ( PROBE-IT ) Study double-blind , randomize , two-arm parallel group , placebo-controlled design compare effect heart rate reduction ventricular reverse remodeling ( assessed LVEF change 24 week ) beta1-gene signal network NYHA Class I-III HFrEF patient idiopathic dilate cardiomyopathy etiology ( HFrEF/IDC ) , sinus rhythm whose heart rate remain ≥ 70 bpm target maximally tolerated dos beta-blockers evidence non-response LVEF ( &lt; 5 absolute percentage point ) . Eligible patient randomize ( 2:1 ) blind treatment ivabradine match placebo initiate per Corlanor® prescribe information 4 week . The dose 4 week post randomization consider intention-to-treat end titration dose , dose adjustment make base clinical factor . The primary endpoint , i.e. , effect heart rate reduction reverse remodeling ( LVEF ) , assess 24 week . LV phenotyping 3D-echocardiography , endomyocardial biopsy coronary sinus sample cardiac norepinephrine level perform baseline 24 week . Exercise test baseline perform assess level beta blockade . Upon completion study , gene expression endomyocardial biopsy tissue sample patient quantify use RNA-seq quantified respect phenotypic measurement include LVEF heart rate change . After Week 24 Visit , patient return End-of-Study Visit offer open label ivabradine dose initiation accomplish stop study drug start Corlanor 5 mg BID 2.5 mg BID patient take dose study drug . Investigators patient inform blinded study drug assignment time study completion .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Atrial Remodeling</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . History nonischemic ( confirmed coronary angiogram ) , nonvalvular dilate cardiomyopathy consider idiopathic , HFrEF NYHA Class I , II , III . 3 . Must experience sign symptom clinical heart failure time within precede 12 month . 4 . In sinus rhythm Screening Visit . 5 . Resting HR ≥ 70 bpm Screening Visit . 6 . Receiving guidelineindicated oral reninangiotensinadosterone system ( RAAS ) inhibitor therapy Randomization Visit , i.e. , ACE inhibitor , angiotensin receptor blocker , sacubitril/valsartan plus mineralocorticoid receptor antagonist tolerate . 7 . May ICD CRT device indicate . 8 . Receiving betablocker therapy ≥ 6 month target dose ≥ 3 month prior Baseline Visit . Target dose carvedilol 25 mg BID , metoprolol succinate , 150 mg/day . Patients receive dos least target level heart failure betablocker uptitrated target LVEF remeasured 3 month , time could eligible enrollment . Patients &lt; target dos intolerant high target dos may enrol . 9 . Evidence stable decline LVEF , define increase ≥ 5 % measurement do within 6 month screen compare recent historical measurement perform within 36 month index measure . Must dose ≥ 50 % target period document lack reverse remodel response . Prior LVEF measurement could perform image technique , e.g. , echocardiography , radionuclide method , MRI , contrast ventriculography . 10 . Women childbearing potential must negative serum pregnancy test Screening Visit negative urine pregnancy test Baseline Randomization Visits . . Women surgically sterile postmenopausal least 12 month consider childbearing potential . 11 . Women childbearing potential must agree use highly effective contraception duration trial least 30 day follow last dose study drug . 12 . Must competent understand information give Institutional Review Board ( IRB ) inform consent form ( ICF ) . 13 . Echocardiographic parasternal window adequate measure LV volumes 3Decho . 14 . Must sign ICF prior initiation study procedure withdraw consent prior Randomization Visit . 1 . NYHA Class IV symptom Randomization Visit . 2 . History HF due associate uncorrected primary valvular disease history ischemic heart disease . 3 . Any history atrial fibrillation ( even sinus rhythm present ) . 4 . Systolic blood pressure &lt; 90/50 mmHg Screening Visit . 5 . Significant fluid overload Randomization Visit , opinion Investigator . Evidence significant fluid overload may include : 1 . Mean jugular venous pressure clavicle 90° . 2 . Liver congestion . 3 . Moist pulmonary rale postcough . 4 . Peripheral edema beyond 1+ pedal explain local factor . 6 . History untreated symptomatic bradycardia symptomatic bradycardia likely full dose study drug opinion Investigator . 7 . Moderate severe asthma obstructive lung disease require chronic use ( &gt; 2 days/week ) inhale β2selective adrenergic agonist &lt; 7 day Randomization Visit . 8 . Untreated thyroid disease , opinion Investigator , Randomization Visit . 9 . Serum potassium &lt; 3.5 mmol/L Screening Visit . . Lab value assess central lab Screening Visit exclusionary result must correct prior randomization document either central local lab . 10 . Renal failure require dialysis , serum creatinine &gt; 2.5 mg/dL , estimate creatinine clearance &lt; 30 mL/min ( CockcroftGault ) Screening Visit . . Lab value assess central lab Screening Visit exclusionary result must correct prior randomization document either central local lab . 11 . Significant intrinsic liver disease total bilirubin &gt; 2.5 mg/dL Screening Visit . . Lab value assess central lab Screening Visit exclusionary result must correct prior randomization document either central local lab . 12 . Participation clinical study treatment investigational drug device within 30 day Screening Visit ( 5 halflives investigational agent , whichever long ) . 13 . Comorbid condition illness , opinion Investigator , may limit life expectancy le 5 year . 14 . Serious active medical psychiatric condition , opinion Investigator , may interfere treatment , assessment , compliance protocol . 15 . History alcohol , drug , chemical abuse , opinion Investigator , could impair limit patient 's full participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>leave ventricular reverse remodel</keyword>
	<keyword>beta-1 adrenergic receptor signal</keyword>
	<keyword>idiopathic dilate cardiomyopathy</keyword>
	<keyword>HCN4 inhibition</keyword>
	<keyword>beta-1 adrenergic receptor blocker</keyword>
	<keyword>gene expression</keyword>
</DOC>